Cargando…

Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader

Despite its inclusion in pneumococcal conjugate vaccine 13 (PCV13), Streptococcus pneumoniae serotype 3 remains a major cause of invasive pneumococcal disease in England and Wales. Previous studies have indicated that there are distinct lineages within serotype 3 clonal complex 180 and the clade dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Groves, Natalie, Sheppard, Carmen L., Litt, David, Rose, Samuel, Silva, Ana, Njoku, Nina, Rodrigues, Sofia, Amin-Chowdhury, Zahin, Andrews, Nicholas, Ladhani, Shamez, Fry, Norman K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896183/
https://www.ncbi.nlm.nih.gov/pubmed/31731573
http://dx.doi.org/10.3390/genes10110845
_version_ 1783476726174580736
author Groves, Natalie
Sheppard, Carmen L.
Litt, David
Rose, Samuel
Silva, Ana
Njoku, Nina
Rodrigues, Sofia
Amin-Chowdhury, Zahin
Andrews, Nicholas
Ladhani, Shamez
Fry, Norman K.
author_facet Groves, Natalie
Sheppard, Carmen L.
Litt, David
Rose, Samuel
Silva, Ana
Njoku, Nina
Rodrigues, Sofia
Amin-Chowdhury, Zahin
Andrews, Nicholas
Ladhani, Shamez
Fry, Norman K.
author_sort Groves, Natalie
collection PubMed
description Despite its inclusion in pneumococcal conjugate vaccine 13 (PCV13), Streptococcus pneumoniae serotype 3 remains a major cause of invasive pneumococcal disease in England and Wales. Previous studies have indicated that there are distinct lineages within serotype 3 clonal complex 180 and the clade distributions have shifted in recent years with the emergence of clade II. We undertook whole genome sequencing and genomic analysis of 616 serotype 3 isolates from England and Wales between 2003 and 2018, including invasive and carriage isolates. Our investigations showed that clade II has expanded since 2014 and now represents 50% of serotype 3 invasive pneumococcal disease (IPD) isolates in England and Wales. Genomic analysis of antibiotic resistance and protein antigen genes showed that distinct profiles are present within the clades which could account for the recent emergence of this clade. This investigation highlights the importance and utility of routine whole genome sequencing and its ability to identify new and emerging variation at the single nucleotide level which informs surveillance and will impact future vaccine development.
format Online
Article
Text
id pubmed-6896183
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68961832019-12-23 Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader Groves, Natalie Sheppard, Carmen L. Litt, David Rose, Samuel Silva, Ana Njoku, Nina Rodrigues, Sofia Amin-Chowdhury, Zahin Andrews, Nicholas Ladhani, Shamez Fry, Norman K. Genes (Basel) Article Despite its inclusion in pneumococcal conjugate vaccine 13 (PCV13), Streptococcus pneumoniae serotype 3 remains a major cause of invasive pneumococcal disease in England and Wales. Previous studies have indicated that there are distinct lineages within serotype 3 clonal complex 180 and the clade distributions have shifted in recent years with the emergence of clade II. We undertook whole genome sequencing and genomic analysis of 616 serotype 3 isolates from England and Wales between 2003 and 2018, including invasive and carriage isolates. Our investigations showed that clade II has expanded since 2014 and now represents 50% of serotype 3 invasive pneumococcal disease (IPD) isolates in England and Wales. Genomic analysis of antibiotic resistance and protein antigen genes showed that distinct profiles are present within the clades which could account for the recent emergence of this clade. This investigation highlights the importance and utility of routine whole genome sequencing and its ability to identify new and emerging variation at the single nucleotide level which informs surveillance and will impact future vaccine development. MDPI 2019-10-25 /pmc/articles/PMC6896183/ /pubmed/31731573 http://dx.doi.org/10.3390/genes10110845 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Groves, Natalie
Sheppard, Carmen L.
Litt, David
Rose, Samuel
Silva, Ana
Njoku, Nina
Rodrigues, Sofia
Amin-Chowdhury, Zahin
Andrews, Nicholas
Ladhani, Shamez
Fry, Norman K.
Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader
title Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader
title_full Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader
title_fullStr Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader
title_full_unstemmed Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader
title_short Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader
title_sort evolution of streptococcus pneumoniae serotype 3 in england and wales: a major vaccine evader
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896183/
https://www.ncbi.nlm.nih.gov/pubmed/31731573
http://dx.doi.org/10.3390/genes10110845
work_keys_str_mv AT grovesnatalie evolutionofstreptococcuspneumoniaeserotype3inenglandandwalesamajorvaccineevader
AT sheppardcarmenl evolutionofstreptococcuspneumoniaeserotype3inenglandandwalesamajorvaccineevader
AT littdavid evolutionofstreptococcuspneumoniaeserotype3inenglandandwalesamajorvaccineevader
AT rosesamuel evolutionofstreptococcuspneumoniaeserotype3inenglandandwalesamajorvaccineevader
AT silvaana evolutionofstreptococcuspneumoniaeserotype3inenglandandwalesamajorvaccineevader
AT njokunina evolutionofstreptococcuspneumoniaeserotype3inenglandandwalesamajorvaccineevader
AT rodriguessofia evolutionofstreptococcuspneumoniaeserotype3inenglandandwalesamajorvaccineevader
AT aminchowdhuryzahin evolutionofstreptococcuspneumoniaeserotype3inenglandandwalesamajorvaccineevader
AT andrewsnicholas evolutionofstreptococcuspneumoniaeserotype3inenglandandwalesamajorvaccineevader
AT ladhanishamez evolutionofstreptococcuspneumoniaeserotype3inenglandandwalesamajorvaccineevader
AT frynormank evolutionofstreptococcuspneumoniaeserotype3inenglandandwalesamajorvaccineevader